EligibleTrials

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

Recruiting · NCT05931276 · Interventional (participants receive a specific treatment) · Lead sponsor: VA Office of Research and Development

View the official record on ClinicalTrials.gov →
Chronic kidney disease

Interventions studied

CarvedilolMetoprolol Succinate

What this trial is about

The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

8 locations listed across 8 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.